20-08-2021, 11:35 AM
According to reliable sources, the Hyderabad-based company is currently engaged in immunogenecity studies of the vaccine in the 2-18 years age group after ‘satisfactory’ outcome in the clinical trials.
https://www.thehindubusinessline.com/com...004481.ece
https://www.thehindubusinessline.com/com...004481.ece